Frontline Ivosidenib/Azacitidine Combo Shows Early Promising Efficacy in IDH1+ AML … pyrexia (44%), vomiting (35%), fatigue (35%), hypokalemia (35%), dizziness (35%), neutropenia (35%), insomnia (35%), and back pain (30%). Source: back pain